Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
3.9
-135.58%
40%
—
389.20%
60%
—
5 Years
Score3.9
Net Growth-135.58%
Net Trend40%
Net Income Consistency—
Rev Growth389.20%
Rev Trend60%
Revenue Consistency—
4D Molecular Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 13M to $ 85M and net income went from -$ 56M to -$ 140M. Revenue increased in 3 of those 5 years; net income in 2.
4D Molecular Therapeutics Inc currently holds a 5-year HDB Score of 3.9 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 11.87 | — |
1 Year2025-08-12 | $ 6.15 | 93.01% |
5 Years2021-08-12 | $ 27.90 | -57.46% |
All Time2020-12-11 | $ 40.50 | -70.69% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2020-12-11 |
|---|---|---|---|---|
| Price | $ 11.87 | $ 6.15 | $ 27.90 | $ 40.50 |
| Return | — | 93.01% | -57.46% | -70.69% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 88M | -$ 160M | $ 390M |
| 2025 | $ 85M | -$ 140M | $ 402M |
| 2024 | $ 37K | -$ 160M | $ 424M |
| 2023 | $ 20M | -$ 100M | $ 288M |
| 2022 | $ 3M | -$ 101M | $ 213M |
| 2021 | $ 18M | -$ 68M | $ 247M |
| IPO2020 | $ 13M | -$ 56M | $ 276M |
Explore beyond FDMT
You're looking at 4D Molecular Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
